BioGaia AB (BIOG B) - Financial and Strategic SWOT Analysis Review

BioGaia AB (BIOG B) - Financial and Strategic SWOT Analysis Review


- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

BioGaia AB (BioGaia) is a healthcare company that develops, markets and sells probiotic products. The company sells its probiotic food supplements and health products in various dosage forms, including drops, lozenges, chewable tablets, oral rehydration solutions (ORS), capsules, powders and ointments. BioGaia's products are based on various strains of Lactobacillus reuteri, its patented lactic acid bacterium. The company's major product areas include child and adult gut health, and, immune, oral, skin and bone health. The company sells its products through its distributors in the APAC (Asia and the Pacific), EMEA (Europe, Middle East, and Africa) and the Americas (South America, Canada and the US). BioGaia is headquartered in Stockholm, Sweden.BioGaia AB Key Recent Developments

Jul 23,2024: Biogaia Releases Interim Management Statement for January – June 2024
Jul 19,2024: BioGaia Signs a Distribution Agreement with Recordati in Italy
May 07,2024: BioGaia AB: Interim Management Statement January – March 2024
Feb 07,2024: BioGaia : Year-end report January – December 2023

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
BioGaia AB - Key Facts
BioGaia AB - Key Employees
BioGaia AB - Key Employee Biographies
BioGaia AB - Major Products and Services
BioGaia AB - History
BioGaia AB - Company Statement
BioGaia AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
BioGaia AB - Business Description
Business Segment: Adult Health
Overview
Performance
Business Segment: Other
Overview
Performance
Business Segment: Pediatrics
Overview
Performance
Geographical Segment: Americas
Performance
Geographical Segment: Asia Pacific
Performance
Geographical Segment: EMEA
Performance
R&D Overview
BioGaia AB - Corporate Strategy
BioGaia AB - SWOT Analysis
SWOT Analysis - Overview
BioGaia AB - Strengths
BioGaia AB - Weaknesses
BioGaia AB - Opportunities
BioGaia AB - Threats
BioGaia AB - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
BioGaia AB, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jul 23, 2024: Biogaia Releases Interim Management Statement for January – June 2024
Jul 19, 2024: BioGaia Signs a Distribution Agreement with Recordati in Italy
May 07, 2024: BioGaia AB: Interim Management Statement January – March 2024
Feb 07, 2024: BioGaia : Year-end report January – December 2023
Oct 20, 2023: BioGaia: Interim report third quarter January - September 2023
Oct 18, 2023: BioGaia’s Nomination Committee for the 2024 Annual General Meeting
Oct 16, 2023: Biogaia’s Results for the Third Quarter to Exceed Market Expectations
Oct 13, 2023: Invitation to Media and Analyst Briefing for BioGaia Q3 2023 Report
Sep 25, 2023: BioGaia Announces Appointment of Theresa Agnew as CEO
Aug 07, 2023: Biogaia and University of Gothenburg Reach an Important Milestone Towards Next-Generation Probiotics
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
BioGaia AB, Key Facts
BioGaia AB, Key Employees
BioGaia AB, Key Employee Biographies
BioGaia AB, Major Products and Services
BioGaia AB, History
BioGaia AB, Other Locations
BioGaia AB, Subsidiaries
BioGaia AB, Key Competitors
BioGaia AB, Ratios based on current share price
BioGaia AB, Annual Ratios
BioGaia AB, Annual Ratios (Cont...1)
BioGaia AB, Annual Ratios (Cont...2)
BioGaia AB, Interim Ratios
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
BioGaia AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
BioGaia AB, Performance Chart (2019 - 2023)
BioGaia AB, Ratio Charts
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
BioGaia AB, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings